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ABSTRACT 
Objective: The objective of this selective EBM review is to determine whether or not long-term 
antibiotic treatments are safe and effective in treating patients 16 and older with disseminated 
Lyme disease? 
 
Study Design: Systematic review of three randomized controlled trials (RCTs) published in peer 
reviewed journals between 2010-2014, all English language. 
 
Data Sources: The three randomized controlled trials were found using PubMed. 
 
Outcomes Measured:  
Two of the studies measured quality of life using RAND-36 Health Status Inventory. The third 
study measured patients’ symptoms using a visual analogue scale. 
 
Results:  All three studies found no significant change in the quality of life or in patients’ 
symptoms when comparing extended antibiotic courses to placebo when treating persistent 
disseminated Lyme.  Two studies had relatively low numbers needed to harm when looking at 
adverse events. 
 
Conclusions: Based on the information provided by these three RCTs, it can be concluded that 
long-term antibiotic treatments are not safe or effective in treating patients 16 and older with 
disseminated Lyme disease. Both antibiotic treatments studied had adverse events and increasing 
duration did not improve quality of life or reduce symptoms any more than the placebo 
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INTRODUCTION 
 Lyme disease is the most common tick-bourne infection in the United States as well as in 
Europe.  It is a spirochetal disease caused by Borrelia burgdorferi that is transmitted by the Ixodes 
tick family.1,2 Lyme disease has three stages that starts with a localized infection and progresses 
to early dissemination and late persistent stage.1,2 When patients continue to have early 
disseminated or late persistent symptoms after their course of antibiotics it is referred to as Post 
Treatment Lyme Disease Syndrome (PTLDS) or chronic Lyme.3 
Although Lyme disease is the most prevalent vector-borne illness reported in the United 
States, it predominately affects the northeastern coast and upper midwest with 96% of cases 
occurring in 14 states.4  Over 30,000 cases of Lyme disease are reported yearly but studies suggest 
that over 376,000 people are diagnosed yearly.2,4  Of those diagnosed, roughly 10-20% of patients 
have remaining symptoms.1,4  Discrepancies between the number of cases reported and diagnosed 
could be caused by inconsistent reporting practices from state to state.   Due to the high prevalence 
of Lyme disease it is estimated that anywhere from 712 million to 1.3 billion dollars are spent 
yearly on Lyme disease and PTLDS.4 It is unknown how many office visits are contributed to 
Lyme disease but research shows that having one chronic Lyme symptom increases outpatient 
visits by 66% over a one year period.4  
Localized infection occurs after the tick-bite and classically begins with erythema migrans 
and flu-like symptoms before disseminating hematogenously causing musculoskeletal, neurologic, 
cardiac complications. Lyme disease can continue to spread in late persistent stage initiating 
arthritis and chronic neurologic deficits.  The exact cause of PTLDS is still unknown.  Evidence 
suggest that it is not caused by a current infection and is liken to some auto-immune conditions.1,2,3 
Localized and early disseminated infections are commonly treated with doxycycline 100mg PO 
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bid or alternatively with amoxicillin 500mg PO TID for 2-3 weeks.1,2,5,6,7 For patients with Lyme 
arthritis the antibiotic course should be for 30 days. With neurologic or cardiac involvement 
ceftriaxone IV for 2-3 weeks is recommended.1 
Patients can continue to have Lyme disease symptoms even after being treated with the 
above antibiotic regimens. There is controversy on the proper treatment for persistent 
disseminated Lyme symptoms. This paper explores the safety and efficacy of extending 
antibiotic treatment in the hopes of reducing disseminated Lyme and persistent symptoms. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not long-term 
antibiotic treatments are safe and effective in treating patients 16 and older with disseminated 
Lyme disease? 
METHODS 
The studies used in this systematic review included three randomized, double-blind, 
placebo controlled clinical trials (RCT). The population studied included patients over 16 years 
old with disseminated Lyme disease. The intervention used in each of the studies was extended 
antibiotic treatments. The population was compared to a placebo group who only received a 
placebo. The outcomes measured in the studies included quality of life, symptoms, and safety. 
All articles were published in English language in peer-reviewed journals. All studies were 
discovered using the keywords “Lyme disease” and “anti-bacterial agents” using the PubMed 
database. The studies were chosen based on their relevance to the clinical question and had 
patient oriented outcomes (POEMS). Inclusion criteria for the sources were randomized, 
controlled, and double-blind studies that measured POEMS for patients with Lyme disease. 
Brown, Extended Antibiotics and Lyme Disease, 3 
 
Articles were excluded if they were written over 10 years ago, involved patients under the age of 
16, and were meta-analyses. The statistics used in this review includes p values, mean change 
from baseline, relative risk increase (RRI), absolute risk increase (ARI), numbers needed to harm 
(NNH), relative benefit increase (RBI), absolute benefit increase (ABI), and numbers needed to 
treat (NNT). The specific studies demographics and characteristics can be found in Table 1. 
Table 1 - Demographics & Characteristics of Included RCTs 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Berende 
(2016)5 
RCT 280 48.7± 
11.8 
 
 
16 years or older 
 
Complaints of 
musculoskeletal 
pain, sensory 
disturbances, 
neuropsych 
disorders, or 
cognitive 
disorders related 
to erythema 
migrans or 
proven Lyme 
borreliosis 
 
Written informed 
consent form 
  
Pregnancy; 
Allergic to 
antibiotics, 
recent therapy < 
4 wks ago; Dx of 
neuroborreliosis, 
immune 
disorders, 
spirochetal ds, 
liver ds, or co-
morbidities;  
Taking cisapride, 
astemizole, 
terfenadine, 
barbiturates, 
phenytoin, 
carbamazepine, 
or OCP; Enrolled 
in other trial  
45 Doxycycline 100 
mg PO BID X 12 
weeks 
 
 
Cameron 
(2008)6 
RCT 86 18-82 At least 16 years 
old 
 
Recurrent Lyme 
disease 
symptoms after 
previous 
successful 
treatment 
 
Inadequate initial 
antibiotic tx or 
amoxicillin 
allergy; Newly 
positive ELISA, 
IgM western blot 
or new infection; 
Other dx 
contributing to 
symptoms 
38 Amoxicillin 3 g PO 
q X 3 months 
 
Oksi 
(2007)7 
RCT 145 19-87 Clinical Lyme dx 
confirmed by 
microbiological 
tests  
 
Intent-to-treat 
 
Penicillin or 
cephalosporin 
allergy; < 16 
years old; 
Pregnancy; 
Antibiotic tx 
within 1 month 
7 Amoxicillin 1g 
BID x 100 days 
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OUTCOMES 
Two of the studies measured quality of life using RAND-36 Health Status Inventory. The 
third study, Oksi et al., measured patients’ symptoms using a visual analogue scale (VAS) 
completed by the participants.  The VAS valued from 0 to 100 where 0 meant symptom free, 50 
represented baseline before any invention, and 100 showing worsen in symptoms.  
RESULTS 
 All three RCTs used extended antibiotic treatment compared to placebo.  Two studies 
used amoxicillin as their antibiotic and the third used doxycycline.  Berende et al. and Oksi et al. 
both initially treated with 2g of IV ceftriaxone for 2 and 3 weeks respectively before introducing 
the intervention.5,7 While Cameron population consisted of patients who were already treated for 
Lyme disease but had a recurrence of symptoms.6 The three studies were similar in that they all 
included participants 16 years and older that presented with arthralgia, cardiac, or neurologic 
involvement with confirmed Lyme disease.  The RCTs also excluded patients with allergies to 
antibiotics, recent antibiotic use, and pregnancy to avoid further complications and encourage 
compliance.  Cameron conducted the study in a primary care internal medicine practice in New 
York and Oksi et al. was conducted in 3 different hospitals in Finland.  Berende et al. was 
performed at two medical centers in Netherlands. 
 Oksi et al. further categorized their participants into definite and possible cases for 
disseminated Lyme borreliosis.  This was based on symptoms, signs, and laboratory signs by the 
end of the trial. Patients categorized with a possible diagnosis had a clinical picture of 
disseminated Lyme but either had no microbiological confirmation or had microbiological 
confirmation but symptoms could be contributed to another cause or condition. This paper 
reviews the results of the cases labeled definite. Oksi et al. enrolled 145 participants, 73 receive 
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amoxicillin and 72 received the placebo.  Of those, 54 in the amoxicillin group were definite and 
52 in the placebo group.  The study had a total of 7 withdraws due to lack of compliance or 
another diagnosis contributing to symptoms was discovered.   
In the Berende et al. trial, 86 patients started in the doxycycline group and only 65 (75%) 
were included in the per-protocol analysis.  The placebo group started with 98 people and ended 
with 74 (75%) in their analysis for a total of 45 dropouts (24.5%) between the two groups. 
Cameron had started with a small sample population of 86 Lyme disease patients in 
which 52 were assigned to the amoxicillin group.  At the end of the study only 31 amoxicillin-
assigned and 17 placebo- assigned patients were evaluated with 38 withdrew. 
 The outcomes in all three articles did not differ significantly from their (p > .05) baseline 
for either patient’s quality of life or symptoms (Table 2).  Berende et al. measured patient’s 
physical quality of life (QOL) using SF-36 physical component score and compared the mean 
change from baseline of those treated with doxycycline to those on the placebo.  The difference 
was .2 with a 95% CI (-2.1 to 2.8) and a p-value of .69.  Cameron also measured the same 
outcome and had a difference of 1.5 with a non-significant p-value when comparing change in 
baseline of amoxicillin to the placebo.  Oksi et al. on the other hand measure patient’s symptoms 
by using VAS and report 0 difference and p-value of .37 in mean change from baseline when 
comparing amoxicillin and placebo.  Oski et al. also reported that 92.5% of patients with definite 
Lyme borreliosis had reported an excellent or good outcome with amoxicillin treatment 
compared 87% of the placebo group with a p-value of .49. Excellent and good outcomes were 
defined as a VAS less than 30.  This data was converted into a dichotomous format to evaluate 
efficacy by getting a value of 19 for the number needed to treat (NNT) as shown in Table 3. 
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Table 2: Comparison of Efficacy through Mean Change from Outcome Baseline 
Study Outcome Mean change 
from baseline 
95% CI P-value 
Berende 5 Physical QOL .2  (-2.1 to 2.8) .69 
Cameron6 Physical QOL 1.5 N/A Non-significant 
Oski7 Symptoms 0 N/A .37 
 
Table 3: Statistical Analysis of Oksi et al7 Efficacy in Improving Symptoms 
CER EER RBI ABI NNT 
.870 .925 .063 .055 18.18  19 
 
Adverse events data from two trials (Table 4) was reported as continuous data and was 
later converted into dichotomous format to evaluate safety of treatment.  Berende et al. reported 
adverse events in 54.7% of those taking Doxycycline and 42.9%% of those taking placebo, 
resulting in a number needed to harm (NNH) of 8 with a p-value of 0.27. A NNH of 8 means that 
for every 8 people treated with doxycycline, 1 adverse event will occur in an additional patient 
that would not have occurred using the placebo.  The most common adverse reactions reported 
during this trial for doxycycline were photosensitivity, nausea, diarrhea, and rash. Cameron 
reported adverse events occurring in 39% of those taking amoxicillin compared to 35% taking 
the placebo with a non-significant p-value. The calculated NNH came out to 25. Diarrhea, yeast 
infections, and nausea were the highest reported adverse events on amoxicillin. 
Table 4: Comparison of Adverse Events and Tolerability 
Study CER (Placebo) EER  RRI ARI NNH 
Berende5 .429 .547 
(doxycycline) 
.275 .118 8.47  8 
Cameron6 .35 .39 
(amoxicillin) 
.114 .04 25 
 
DISCUSSION 
There are several limitations among these three trials.  The first is that the duration of the 
patient’s symptoms varied before receiving the treatment or be influenced by an undiagnosed 
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active infection.  The three studies also had small population sizes which reduces the validity of 
the studies. Cameron trial experienced a high drop- out rate with over 55% of the enrollees 
withdrew from the trial.  Berende et al. also had a notable withdraw rate of 24.5%.  This lowers 
sample size and reduces validity.  These high drop-out rates and non-compliance could be 
contributed to adverse events to the antibiotics and the extend course.  What might have been 
tolerable for a short course, such as diarrhea and nausea may not be so when extended to 60-100 
days.  
Both Berende et al. and Oksi et al. had similar limitations within their trials and in 
application to other populations.  Participants in these two studies did not have any previous 
treatment for Lyme disease.  It would have been unethical to not initially treat them with 
ceftriaxone, and thus only explored extended adjunctive therapy.  It is also unknown if this data 
correlates to patients in the United States, as both trials were performed only in Europe. The 
genospecies of Borrelia burgdorferi may vary from continent to continent.  The Cameron Trial, 
although performed in New York, was only conducted at a single location and therefore has a 
lower generalizability than the multi-site trials.  Although these trials have their own limitations, 
collectively they support each other with similar findings.  
The two interventional antibiotics used in these three studies, amoxicillin and 
doxycycline, are both generic antibiotics that are readily available in the United States with a 
prescription. They are both relatively inexpensive, and insurance should provide some coverage.  
Amoxicillin has both gram positive and negative coverage, and is also used commonly in ear, 
nose, and throat infections, eradication of H. pylori in PUD, and used in pregnancy to treat 
urinary tract infections.8  Amoxicillin is used in pregnancy and breast feeding but there is 
conflicting data on teratogenicity risk.8  Patients can have anaphylactic or hypersensitivity 
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reactions to this antibiotic especially in those who have a penicillin allergy.  Doxycycline is used 
for a variety of different conditions ranging from acne, to sexual transmitted infections, malaria 
prophylaxis, and rocky mountain spotted fever.9  Doxycycline, however is less tolerable and has 
more adverse events such as GI inflammation and upset, hypersensitivities such as Stevens- 
Johnson syndrome or toxic epidermal necrosis, and photosensitivity.9  Doxycycline is 
contraindicated in pregnancy, breast feeding, and children under the age of 8 for potential 
teratogenic risks, and accumulation in developing teeth and long bones.9   
  There are other various treatments that have been provided for patients with persistent 
disseminate Lyme disease.  These various treatments, including long courses of antibiotics, do 
not having supporting data and have left some patients with harmful complications such as septic 
shock, osteomyelitis, Clostridium difficile colitis, and paraspinal abscesses.10   
CONCLUSIONS 
Based on the information provided by these three RCTs, it can be concluded that long-
term antibiotic treatments are not safe or effective in treating patients 16 and older with 
disseminated Lyme disease.  Both antibiotic treatments studied, doxycycline and amoxicillin had 
adverse events such photosensitivity, rash, nausea, and most commonly diarrhea.  The three 
RCTs showed that extending the duration of antibiotics in treating Lyme disease did not improve 
quality of life or reduce symptoms any more than the placebo. These studies however did not 
consider other antibiotics or expanded the initial use of ceftriaxone.  Nor did these studies 
investigate treating patients with local Lyme disease with a longer duration of antibiotic reduces 
the prevalence of disseminated or chronic Lyme disease.  It might be beneficial to explore these 
topics in future studies.
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